These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6593751)

  • 1. Long-term effects of fenofibrate on serum lipids and on lipoprotein cholesterol in type II hyperlipoproteinemic patients.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Cabrini E; Fasoli A
    Pharmacol Res Commun; 1984 Aug; 16(8):809-20. PubMed ID: 6593751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate therapy of hypertriglyceridaemia. Differential effects on LDL cholesterol level in type IV and in type IIb primary hyperlipoproteinaemia.
    Sommariva D; Bonfiglioli D; Pogliaghi I; Ottomano C; Fasoli A
    Eur J Clin Pharmacol; 1984; 26(6):741-4. PubMed ID: 6489413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fenofibrate and colestipol: effects on serum and lipoprotein lipids and apolipoproteins in familial hypercholesterolaemia.
    Weisweiler P; Merk W; Jacob B; Schwandt P
    Eur J Clin Pharmacol; 1986; 30(2):191-4. PubMed ID: 3709644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of fenofibrate on plasma lipids. Double-blind, multicenter study in patients with type IIA or IIB hyperlipidemia.
    Brown WV; Dujovne CA; Farquhar JW; Feldman EB; Grundy SM; Knopp RH; Lasser NL; Mellies MJ; Palmer RH; Samuel P
    Arteriosclerosis; 1986; 6(6):670-8. PubMed ID: 3535757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multicenter comparison of micronized fenofibrate and simvastatin in patients with primary type IIA or IIB hyperlipoproteinemia.
    Steinmetz A; Schwartz T; Hehnke U; Kaffarnik H
    J Cardiovasc Pharmacol; 1996 Apr; 27(4):563-70. PubMed ID: 8847874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between plasma fenofibric acid levels and the effect of micronized fenofibrate on cholesterol, low-density-lipoprotein cholesterol and apolipoprotein B in patients with primary hypercholesterolemia.
    Raslová K; Dubovská D; Mongiellová V; Trnovec T
    Eur J Clin Pharmacol; 1997; 52(2):101-6. PubMed ID: 9174678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.
    Insua A; Massari F; Rodríguez Moncalvo JJ; Rubén Zanchetta J; Insua AM
    Endocr Pract; 2002; 8(2):96-101. PubMed ID: 11942772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fenofibrate therapy of hyperlipoproteinaemia. A dose-response study and a comparison with clofibrate.
    Rössner S; Orö L
    Atherosclerosis; 1981; 38(3-4):273-82. PubMed ID: 7225166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.
    Tribble DL; Farnier M; Macdonell G; Perevozskaya I; Davies MJ; Gumbiner B; Musliner TA
    Metabolism; 2008 Jun; 57(6):796-801. PubMed ID: 18502262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D; Griglio S; Le Naour G; Chapman MJ
    Atherosclerosis; 2001 Mar; 155(1):251-60. PubMed ID: 11223449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.
    Leiss O; Meyer-Krahmer K; von Bergmann K
    J Lipid Res; 1986 Jul; 27(7):713-23. PubMed ID: 3760707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia.
    Malmendier CL; Delcroix C
    Atherosclerosis; 1985 May; 55(2):161-9. PubMed ID: 3924068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variations in lipids and proteins of lipoproteins by fenofibrate in some hyperlipoproteinaemic states.
    Avogaro P; Bittolo Bon G; Belussi F; Pontoglio E; Cazzolato G
    Atherosclerosis; 1983 Apr; 47(1):95-100. PubMed ID: 6870993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation between plasma levels of fenofibrate and lipoprotein changes in hyperlipidaemic patients.
    Sirtori CR; Montanari G; Gianfranceschi G; Sirtori M; Galli G; Bosisio E
    Eur J Clin Pharmacol; 1985; 28(6):619-24. PubMed ID: 3840743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF; Barrett PH; Ji J; Serone AP; Chan DC; Croft KD; Loehrer F; Johnson AG
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose colestipol plus fenofibrate: effects on plasma lipoproteins, lecithin:cholesterol acyltransferase, and postheparin lipases in familial hypercholesterolemia.
    Weisweiler P
    Metabolism; 1989 Mar; 38(3):271-4. PubMed ID: 2918846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [One year fenofibrate treatment of type II primary hyperlipidaemia. Effects on lipoproteins and biological tolerance (author's transl)].
    Drouin P; Méjean L; Lambert D; Wülfert E; Debry G
    Nouv Presse Med; 1980 Dec; 9(49):3753-7. PubMed ID: 7208342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long term-effect of fenofibrate on lipoprotein level and composition in different types of genetic hyperlipidemias.
    Baggio G; Gasparotto A; Ciuffetti G; Valerio G; Fellin R; Senin U; Gabelli C; Crepaldi G
    Pharmacol Res Commun; 1986 May; 18(5):471-80. PubMed ID: 3737657
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of fenofibrate on serum lipoproteins in subjects with familial hypercholesterolemia and combined hyperlipidemia.
    Weisweiler P; Merk W; Janetschek P; Schwandt P
    Atherosclerosis; 1984 Dec; 53(3):321-5. PubMed ID: 6529448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.
    Paragh G; Seres I; Harangi M; Balogh Z; Illyés L; Boda J; Szilvássy Z; Kovács P
    Diabetes Metab; 2003 Dec; 29(6):613-8. PubMed ID: 14707891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.